✦ LIBER ✦

Second-line therapy for advanced non-small-cell lung cancer

✍ Scribed by Christine L. Hann; Julie R. Brahmer

Publisher: Current Science Inc.
Year: 2006
Tongue: English
Weight: 90 KB
Volume: 8
Category: Article
ISSN: 1523-3790
DOI: 10.1007/s11912-006-0027-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Second-line therapy with gefitinib in co

Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study

✍ G. Robinet; F. Barlesi; P. Fournel; H. Berard; R. Corre; A. Vergnenegre; L. Falc 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 160 KB

Second–line chemotherapy for non—small–c

Second–line chemotherapy for non—small–cell lung cancer

✍ Frank V. Fossella 📂 Article 📅 2000 🏛 Current Science Inc. 🌐 English ⚖ 225 KB

Advanced non-small cell lung cancer

✍ Martin J. Edelman; Shyam L. Khanwani 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 329 KB

Third-line therapy for advanced non-smal

Third-line therapy for advanced non-small-cell lung cancer patients: feasible drugs for feasible patients

✍ Zhengbo Song; Yongfeng Yu; Zhiwei Chen; Shun Lu 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 387 KB

Recent advances in etoposide therapy for

Recent advances in etoposide therapy for non-small cell lung cancer

✍ Philip Bonomi 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 504 KB

Non-small cell lung cancer (NSCLC) continues to be a major health problem in the US. In 1990, approximately 120,000 new cases will be diagnosed, and the majority of these patients will have either unresectable disease or resected disease that has a relatively low chance of being cured. A variety of

Docetaxel and mitomycin as second-line t

Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer

✍ J. Feliu; G. Martín; J. Castro; A. Sundlov; A. Rodriguez-Jaráiz; E. Casado; M. L 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 209 KB